Eledon Pharmaceuticals (ELDN) Retained Earnings (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Retained Earnings data on file, last reported at -$440.2 million in Q1 2026.

• Quarterly Retained Earnings fell 21.58% year-over-year to -$440.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$440.2 million (down 21.58% YoY) and the FY2025 annual result came in at -$401.2 million, down 12.83% from the prior year.
• Retained Earnings declined to -$440.2 million in Q1 2026, from -$401.2 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $9000.0 in Q3 2025 to a low of -$440.2 million in Q1 2026.
• A 5-year average of -$275.4 million and a median of -$311.0 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings slumped 108.49% — and 2025, when it surged 100.0%.
• Tracing ELDN's Retained Earnings over 5 years: stood at -$202.9 million in 2022, then slumped by 57.45% to -$319.4 million in 2023, then retreated by 11.33% to -$355.6 million in 2024, then retreated by 12.83% to -$401.2 million in 2025, then declined by 9.72% to -$440.2 million in 2026.
• The last three Retained Earnings figures came in at -$440.2 million (Q1 2026), -$401.2 million (Q4 2025), and $9000.0 (Q3 2025), per Business Quant data.